Combination

The Kingdom of Saudi Arabia and Rezolve AI Ink Pioneering MOU to Establish Global AI Market Leaders

Retrieved on: 
Monday, March 18, 2024
AACI, Combination, Growth, Register, Partnership, Artificial intelligence, Acquisition, Business analyst, Ministry of Investment, KSA, Hallucination, MISA

LONDON, March 18, 2024 (GLOBE NEWSWIRE) -- In a strategic move that highlights the Kingdom of Saudi Arabia's commitment to technological advancement and economic growth, the Ministry of Investment of Saudi Arabia (MISA) has forged a groundbreaking partnership with Rezolve AI Limited. This collaboration is set to revolutionize the artificial intelligence (AI) landscape, establishing an AI Centre of Excellence in Saudi Arabia as a cornerstone of Vision 2030's innovation and development goals.

Key Points: 
  • Upon closing of the transaction, the combined company’s shares are expected to trade on the Nasdaq under the ticker symbol “ZONE”.)
  • This collaboration is set to revolutionize the artificial intelligence (AI) landscape, establishing an AI Centre of Excellence in Saudi Arabia as a cornerstone of Vision 2030's innovation and development goals.
  • • Creation of Global Market Leaders: In partnership with the Ministry of Investment, the goal is to launch at least five AI ventures in diverse market sectors, funded and headquartered locally, each aspiring to become global market leaders.
  • These ventures will leverage Rezolve's cutting-edge AI Large Language Model (brainpowa) to foster innovation and ensure global leadership without succumbing to AI hallucinations.

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Retrieved on: 
Monday, March 18, 2024
Combination, Fibromyalgia, Patent, Chronic pain, SILO, Ketamine, Therapy, Administration, Medical device

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (USPTO).

Key Points: 
  • The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.
  • Silo believes that implantable drug delivery may be well-suited for chronic pain management.
  • “Our SP-26 implant technology is designed to deliver a steady, low dose of ketamine for sustained relief of chronic pain,” said Eric Weisblum, CEO of Silo.
  • If approved, SP-26 could be the first at-home approved ketamine based therapeutic.”
    The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action.

Global Artificial Intelligence Market Expected to Grow to $1.3 Trillion by 2023

Retrieved on: 
Monday, March 18, 2024
Cloud, MSFT, Combination, Google Cloud, Algorithm, Natural language processing, Microsoft, Health, Ink, Social media, Artificial intelligence, Transport, Business analyst, Alphabet Inc., AV1, USD, Marketing, Cloud database, Armada, Automation, Amazon, Partnership, Internet of things, Oracle Cloud, VMW, PALM, BMR, Ministry of Investment, Hallucination, HP, VMware, Register, Microsoft Azure, Organization, Intelligence, Library, Internet, Research, News, Acquisition, PostgreSQL, KSA, Alliance for Open Media, Robotics, ACM, GOOG, ChatGPT, Machine learning, MISA, AACI, Nvidia, Growth, HP Inc., CUDA, NVDA, OCI, Table, A.I, Big, NVIDIA, Medical device

A report from MarketsAndMarkets said that the global artificial intelligence market size was valued at USD 150.2 billion in 2023 and is expected to grow at a CAGR of 36.8% from 2023 to 2030.

Key Points: 
  • A report from MarketsAndMarkets said that the global artificial intelligence market size was valued at USD 150.2 billion in 2023 and is expected to grow at a CAGR of 36.8% from 2023 to 2030.
  • The report added: “The increasing adoption of autonomous artificial intelligence (AI) is driving the growth of the Artificial Intelligence Industry.
  • As technology advances and more industries recognize its benefits, the Artificial Intelligence (AI) Market size is poised for expansion, fostering innovation and new opportunities.”   Active A.I.
  • MarketsAndMarkets continued: “The exponential ai growth statistics of digital data from various sources presents immense opportunities for the AI market.

Broad Capital Acquisition Corp Confirms Funding to Extend Period to Consummate Initial Business Combination to April 13, 2024

Retrieved on: 
Friday, March 15, 2024
Combination, BRAC, Acquisition

Dallas, Texas, March 15, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on March 11, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to April 13, 2024 (the “Monthly Extension”).

Key Points: 
  • Dallas, Texas, March 15, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on March 11, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to April 13, 2024 (the “Monthly Extension”).
  • The Monthly Extension is the third of the twelve monthly extensions permitted under the Company’s Amended and Restated Certificate of Incorporation, as amended to date.
  • On January 18, 2023, the Company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement, as amended (the “Business Combination Agreement”), with Openmarkets Group Pty Ltd, an Australian proprietary limited company (“OMG”), BMYG OMG Pty Ltd, an Australian proprietary limited company, and Broad Capital LLC, a Delaware limited liability company, solely in its capacity as the Company’s sponsor, pursuant to which the Company will enact its initial business combination.

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

KEON CAPITAL INC. EXECUTES DEFINITIVE AGREEMENTS RESPECTING PROPOSED TRANSACTION WITH FRAME HOLDINGS INC.

Retrieved on: 
Wednesday, March 13, 2024
Combination, TSX Venture Exchange, Private, Minority, News, Business analyst, Multilateral, Transaction, Policy, Security (finance)

Vancouver, B.C., March 13, 2024 (GLOBE NEWSWIRE) -- Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) is pleased to provide an update respecting its previously announced transaction (the “Transaction”) with Frame Holdings Inc. (“Frame”) pursuant to which Keon will acquire all of the issued and outstanding Frame shares from the Frame shareholders (see Keon’s news release dated November 6, 2023 announcing the execution of an LOI respecting the Transaction).

Key Points: 
  • Vancouver, B.C., March 13, 2024 (GLOBE NEWSWIRE) -- Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) is pleased to provide an update respecting its previously announced transaction (the “Transaction”) with Frame Holdings Inc. (“Frame”) pursuant to which Keon will acquire all of the issued and outstanding Frame shares from the Frame shareholders (see Keon’s news release dated November 6, 2023 announcing the execution of an LOI respecting the Transaction).
  • The Transaction is structured as a three-cornered amalgamation (the “Amalgamation”), with Frame amalgamating with Subco and becoming a wholly-owned subsidiary of Keon.
  • Shareholders of Frame will receive one common share in the capital of Keon in exchange for each outstanding common share of Frame held by them, with Keon expected to issue an aggregate of approximately 40,000,000 Keon shares (assuming the minimum Frame financing of $2,000,000) to the Frame shareholders under the Transaction.
  • In connection with the Transaction, Keon will conduct a 2.8:1 share consolidation of issued and outstanding Keon common shares (the “Keon Share Consolidation”), and any shares issued to Frame shareholders under the Transaction will be on a post-consolidation basis.

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Retrieved on: 
Tuesday, March 12, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Merck, Cancer, Pembrolizumab, Lung cancer, DLT, Merck & Co., Kineta, NK, Pharmaceutical industry

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • We continue to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Retrieved on: 
Tuesday, April 2, 2024
Medical Devices, FDA, Health, Health Technology, General Health, Pharmaceutical, Eli Lilly, Combination, DCT, Microsoft Research, Artificiality, Trust (social science), GSK, Novartis, Patient, Food and Drug Administration, Artificial intelligence, USS Midway, AI, EMA, Merck & Co., Medicine, European Medicines Agency, Johnson & Johnson, Ecosystem, Drug development, Pharmacovigilance, Food, DIA, Student, Diamond, DEI, Medical device

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.

Key Points: 
  • The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.
  • Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world's preeminent neutral life sciences forum — and the only thing missing is you.
  • "This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we're celebrating by continuing to forge a bold future marked by innovation and impact," said Marwan Fathallah, DIA's President and Global Chief Executive.
  • — An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today's regulatory, scientific, and communication challenges.

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
Tuesday, March 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

New Renesas MCUs with High-Resolution Analog and Over-the-Air Update Support Help Customer Systems Conserve Energy

Retrieved on: 
Thursday, March 21, 2024
Apps, Applications, Mobile, Wireless, Technology, Semiconductor, Security, Software, Networks, Internet, Hardware, Data Management, Combination, Electricity, Temperature, M23, Sigma, Acceleration, Internet of things, Embedded, MCU, Renesas Electronics, FOTA, Digital filter, Ecosystem, BSP, Multimedia, ADC, FSP, AES

RA2A2 MCUs contribute to the digitalization of conventional systems with key features including high-level analog sensing, FOTA support, 8KHz/4KHz hybrid sampling, and AES hardware accelerator functions.

Key Points: 
  • RA2A2 MCUs contribute to the digitalization of conventional systems with key features including high-level analog sensing, FOTA support, 8KHz/4KHz hybrid sampling, and AES hardware accelerator functions.
  • When the end-systems are digitalized, it is possible to analyze individual systems status seamlessly for further energy-efficient, streamlining system operation.
  • The adoption of smart meters with NILM is the most cost-effective and scalable solution for increasing energy efficiency and lowering energy consumption.
  • “Renesas has worked closely with our customers to understand their requirements for next-generation systems that can support critical energy conservation goals,” said Akihiro Kuroda, Vice President of the Embedded Processing 2nd Division at Renesas.